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Abstract
Background: Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and
removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and
safety of gantenerumab in prodromal Alzheimer’s disease (AD).
Methods: In this randomized, double-blind, placebo-controlled phase III study, we investigated gantenerumab over
2 years. Patients were randomized to gantenerumab 105 mg or 225 mg or placebo every 4 weeks by subcutaneous
injection. The primary endpoint was the change from baseline to week 104 in Clinical Dementia Rating Sum of Boxes
(CDR-SB) score. We evaluated treatment effects on cerebrospinal fluid biomarkers (all patients) and amyloid positron
emission tomography (substudy). A futility analysis was performed once 50% of patients completed 2 years of treatment.
Safety was assessed in patients who received at least one dose.
Results: Of the 3089 patients screened, 797 were randomized. The study was halted early for futility; dosing was
discontinued; and the study was unblinded. No differences between groups in the primary (least squares mean
[95% CI] CDR-SB change from baseline 1.60 [1.28, 1.91], 1.69 [1.37, 2.01], and 1.73 [1.42, 2.04] for placebo, gantenerumab
105 mg, and gantenerumab 225 mg, respectively) or secondary clinical endpoints were observed. The incidence of
generally asymptomatic amyloid-related imaging abnormalities increased in a dose- and APOE ε4 genotype-dependent
manner. Exploratory analyses suggested a dose-dependent drug effect on clinical and biomarker endpoints.
Conclusions: The study was stopped early for futility, but dose-dependent effects observed in exploratory analyses on
select clinical and biomarker endpoints suggest that higher dosing with gantenerumab may be necessary to achieve
clinical efficacy.
Trial registration: ClinicalTrials.gov, NCT01224106. Registered on October 14, 2010.
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Background
Alzheimer’s disease (AD) is characterized by the pres-
ence of amyloid plaques and neurofibrillary tangles in
the brain. Amyloid plaques are composed primarily of
aggregated amyloid-beta (Aβ) peptide, which is depos-
ited in the brain parenchyma, likely decades before clin-
ical symptoms manifest [1]. Although the accumulation
of presumably neurotoxic, aggregated Aβ is at the core
of the amyloid hypothesis of AD [2], the specific process
by which Aβ may lead to neuronal death remains un-
clear. Clinical progression has been reported to follow a
predictable pattern, with patients transitioning through a
preclinical stage, followed by a prodromal stage charac-
terized by biomarker findings indicative of accumulating
disease burden and cognitive symptoms not of sufficient
severity to impact patient functioning, and eventually
reaching the dementia stage.
Prior to the initiation of the SCarlet RoAD study
(NCT01224106; WN25203), researchers in most clinical
trials identified patients with mild cognitive impairment
(MCI) using clinical criteria, such as an episodic mem-
ory deficit or Clinical Dementia Rating (CDR) global
score. Heterogeneity of patients with MCI has consist-
ently been identified as a factor hampering the possibil-
ity of identifying a clinical benefit [3]. Subsequently,
research criteria that included biomarkers of AD path-
ology were developed in an attempt to more specifically
identify patients in the prodromal phase of AD [4, 5].
Because cerebrospinal fluid (CSF) levels of Aβ42 have
been found to be low in prodromal AD [6], CSF testing
for low Aβ42 levels was required for inclusion in the
SCarlet RoAD study.
Gantenerumab (RO4909832, RG1450) is a human
anti-Aβ monoclonal antibody that binds with high affin-
ity to aggregated Aβ and promotes its removal by Fc
receptor-mediated phagocytosis [7]. In a phase I study of
16 patients with mild to moderate AD, gantenerumab
treatment resulted in a rapid reduction in brain amyloid
load over the course of 6 months [8]. Gantenerumab
intravenous (IV) doses of 60 mg (equivalent to ~ 100 mg
subcutaneous [SC]) and 200 mg (equivalent to ~ 330 mg
SC) given every 4 weeks were associated with dose-
dependent cortical amyloid standardized uptake value
ratio (SUVr) reduction [8] compared with placebo. At
200 mg IV, apolipoprotein E (APOE) ε4 genotype-
dependent vasogenic edema (amyloid-related imaging
abnormalities [ARIA]-E) and amyloid-related imaging
abnormality microbleeds (ARIA-H) were detected, sug-
gesting an optimal target dose for the investigation of ef-
ficacy above 100 mg but below 330 mg SC. Accordingly,
gantenerumab SC doses of 105 mg and 225 mg given
every 4 weeks were selected for the SCarlet RoAD study,
with APOE ε4 homozygous patients randomized to the
lower dose or placebo only. SCarlet RoAD was the first
phase III study in prodromal AD confirmed by CSF
amyloid analysis with a single primary endpoint, the
CDR Sum of Boxes (CDR-SB). The primary objective
was to evaluate the effect of gantenerumab (105 and
225 mg) compared with placebo on CDR-SB in pro-
dromal AD over the course of 2 years of treatment. In
this paper, we report the efficacy, biomarker, and safety
data available at the time of SCarlet RoAD futility ana-
lysis, including results of preplanned and exploratory
analyses.
Methods
SCarlet RoAD was a phase III, multicenter, randomized,
double-blind, placebo-controlled, parallel-group, 2-year
study of gantenerumab in prodromal AD. The study was
conducted globally across 128 sites. SCarlet RoAD was
approved by individual institutional ethics committees
or institutional review boards and was conducted in ac-
cordance with the principles of the Declaration of
Helsinki and good clinical practice (GCP). Written in-
formed consent was obtained from each patient.
Patients
A total of 3089 patients were screened for eligibility for
this study. The screening period lasted up to 8 weeks,
with rescreening permitted after ≥ 3 months for patients
who did not meet select eligibility criteria. It was recom-
mended that the first screening tests be the CDR, Free
and Cued Selective Reminding Test (FCSRT), and Mini
Mental State Examination (MMSE), in any order. CSF
collection and magnetic resonance imaging (MRI) were
conducted only after neuropsychological, electrocardio-
graphic, and laboratory tests confirmed eligibility. Par-
ticipation in an exploratory amyloid positron emission
tomography (PET) substudy was optional and was not
available at all sites. For patients in this substudy, a posi-
tive screening scan for amyloid PET was required and
was performed once eligibility for the main study had
been confirmed.
Patients in SCarlet RoAD were 50–85 years of age and
met International Working Group criteria for prodromal
AD [4], with biomarker evidence of amyloid pathology
and largely preserved functional abilities such that a
diagnosis of dementia could not be made. Clinical status
was documented by an MMSE score ≥ 24, a CDR global
score of 0.5 with an accompanying memory box score of
0.5 or 1.0, abnormal memory function based on an
FCSRT score of either < 17 free recall, < 40 total recall,
or < 20 free recall, and < 42 total recall; a score ≤ 4 on
the modified Hachinski Ischemic Scale [9]; and absence
of depression documented by a score ≤ 6 on the Geriat-
ric Depression Scale (GDS). Evidence of amyloid path-
ology was required as determined by a CSF Aβ1–42
Ostrowitzki et al. Alzheimer's Research & Therapy  (2017) 9:95 Page 2 of 15
level ≤ 600 ng/L (INNOTEST® Aβ1–42; Fujirebio, Ghent,
Belgium).
Exclusion criteria were neurological disease other than
AD, abnormal brain MRI at screening (including three or
more microhemorrhages [1.5 T], two or more lacunar in-
farcts, extensive/confluent deep white matter lesions, or
any space occupying lesions), a major psychiatric disorder,
and a history of stroke or any clinically unstable medical
illness. Symptomatic treatment with memantine or acetyl-
cholinesterase inhibitors was not permitted at any time
during the study; patients requiring such antidementia
therapy were to be discontinued from the study.
Randomization and masking
The planned sample size was 770, with patients meeting
eligibility criteria randomized to treatment with placebo,
gantenerumab 105 mg SC, or gantenerumab 225 mg SC
every 4 weeks (ratio 2:1 for active placebo). Patients with
zero or one APOE ε4 allele were randomized to any
treatment group, whereas APOE ε4 homozygotes could
be randomized only to placebo or gantenerumab 105 mg
SC. APOE ε4 status was blinded to sponsor, patient, and
investigator. The algorithm for dynamic patient alloca-
tion to treatment was based on minimization with
biased coin assignment. The randomization was strati-
fied by PET substudy participation (participation vs non-
participation), APOE ε4 allele status (0 ε4 vs 1 ε4 vs 2
ε4), and region (Europe vs rest of world). The study was
conducted in a double-blind manner. A potentially un-
blinded person was involved in the preparation of study
medication but was not involved with patient care.
Procedures
Treatment with placebo, gantenerumab 105 mg, or gan-
tenerumab 225 mg was administered SC every 4 weeks
in the abdomen. The gantenerumab drug product was
manufactured by Roche Pharma AG (Grenzach-Wyhlen,
Germany) in accordance with Roche standards and local
regulations.
Clinical outcomes
The primary endpoint was the change from baseline in
CDR-SB at week 104 [10]. Secondary endpoints included
changes in cognition, behavior, and daily function over
104 weeks. Cognition was assessed using the 13-item
Alzheimer’s Disease Assessment Scale–Cognitive sub-
scale (ADAS-Cog 13), the MMSE, a computerized cog-
nitive battery (Cambridge Neuropsychological Test
Automated Battery [CANTAB]), and the FCSRT. Behav-
ior and daily functioning were assessed using the Neuro-
psychiatric Inventory Questionnaire (NPI-Q) and the
Functional Activities Questionnaire (FAQ), respectively.
Clinical assessments were carried out before the first
dose and every 12 weeks thereafter.
Biomarker outcomes
Biomarker assessments included amyloid PET, brain vol-
umes as measured by MRI, CSF concentrations of Aβ1–
42, total tau (t-tau), phosphorylated tau 181 (p-tau), and
neurogranin.
Amyloid PET
Participants in the [18F]florbetapir substudy underwent
PET scanning at baseline and at weeks 20, 60, and 100.
PET acquisition started 50 minutes postinjection, and
three 5-minute frames were acquired. All PET data were
corrected for radioactive decay, scatter, and attenuation.
The data were also assessed for artefacts and patient
motion. All further PET data processing was performed
in PMOD (PMOD Technologies, Zürich, Switzerland).
After motion correction and averaging of the three
frames, the PET scan was coregistered to the cropped,
skull-stripped screening MRI and normalized to the
Montreal Neurological Institute space using the
normalization parameters obtained from the MRI scan.
The [18F]florbetapir global cortical signal was calculated
as the volume-weighted, gray matter-masked average
SUVr [11] of five bilateral cortical regions defined on the
basis of Automated Anatomical Labeling template: anter-
ior and posterior cingulate cortex, parietal, lateral tem-
poral, and frontal cortex [12], using cerebellar cortex as
the reference region for intensity normalization. Other ref-
erence regions investigated included whole cerebellum
and pons.
MRI
MRI was performed using 1.5-T magnets. In exceptional
circumstances, a 3-T magnet was accepted. MRI scans
were obtained for subject screening and safety monitoring
and to determine potential treatment effects on brain vol-
umes. Each time an MRI scan was scheduled, we acquired
near-isotropic 3D T1-weighted gradient echo, axial 5-
mm T2*-weighted gradient echo with a minimum echo
time of 20 milliseconds; T2-weighted spin-echo fluid-
attenuated inversion recovery; and, if available, diffusion-
weighted scans. Images were centrally quality-controlled
and read by a neuroradiologist. Screening, week 48, and
week 104 MRI scans were used for volumetric analysis of
hippocampi, whole brain, and ventricles [13, 14]. Hippo-
campal volume was assessed by trained technicians using
manual tracing. Whole-brain volume change was mea-
sured using the k-means brain boundary shift integral
[14]. Ventricular volume change was measured using the
ventricular boundary shift integral [13].
CSF
CSF was sampled at screening and at weeks 52 (optional)
and 104. Screening samples were analyzed using INNOT-
EST® Aβ1–42 for eligibility assessment. For longitudinal
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analyses, CSF biomarkers from all time points were
measured using the Elecsys® β-Amyloid1–42, t-tau, and
p-tau181P immunoassays (Roche Diagnostics GmbH,
Rotkreuz, Switzerland) [15]. Neurogranin, a biomarker
associated with synaptic dysfunction and degeneration
in AD [16, 17], was evaluated at the clinical neuro-
chemistry laboratory of Dr. Kaj Blennow, Gothenburg,
Sweden, using an in-house enzyme-linked immuno-
sorbent assay [18].
Safety monitoring
Safety was evaluated by reports of adverse events, clin-
ical laboratory testing (hematologic and serum chemis-
try, and urinalysis), vital sign assessments, physical and
neurological examinations, electrocardiography, antidrug
antibody titers, and brain MRI. MRI reads documented
all ARIA-E and ARIA-H, as well as scoring of ARIA-E
using the ARIA-E rating scale (scale range 0–60, with
higher scores indicating greater severity) [19]. All ARIA
were recorded as adverse events and additionally
reviewed by an independent MRI committee, whose re-
ports were shared regularly with the independent data
monitoring committee (IDMC). Patients were queried
about new central nervous system symptoms following
the identification of an ARIA. Upon new ARIA-E findings,
treatment was withheld. MRI was performed approxi-
mately every 4–8 weeks until the ARIA-E had resolved or
clearly decreased and stabilized, upon which, treatment
ensued at half the original dose. If a second ARIA-E oc-
curred, treatment was permanently discontinued.
Treatment modification and discontinuation due to
ARIA-H was based on cumulative numbers of new events
over a 12-month period: if more than four events, treat-
ment was discontinued; if more than two (but less than or
equal to four), the dose was halved. For patients on half-
dose, treatment was to be discontinued if new ARIA-H
events were greater than two since the dose was halved or
within the past 12 months, whichever was shorter. De-
pressive and suicidal symptoms were assessed using the
GDS and the Columbia Suicide Severity Rating Scale.
Statistical analysis
The sample size was calculated to allow ≥ 80% power to
demonstrate an effect size of 0.35 on the primary end-
point (gantenerumab 225 mg vs placebo) at the type I
error level of p ≤ 0.05 (two-sided). Power calculations
were based on simulations of the mixed-effects model
repeated measurement (MMRM) analysis planned for
statistical assessment of the primary efficacy variable.
The primary efficacy outcome—mean change from
baseline on CDR-SB at week 104—was assessed using
MMRM analysis incorporating data up to 104 weeks of
treatment. The model included the change from baseline
in the CDR-SB score as the dependent variable. The
effects in the model included independent variables of
the fixed categorical effects of treatment, assessment
weeks relative to the first dose of study medication (i.e.,
time), treatment-by-time interaction, and APOE ε4
status (carrier vs noncarrier), along with continuous co-
variates of the baseline CDR-SB value and hippocampal
volume at baseline. Time was treated as the repeated
variable within a subject. Subject, treatment, and time
were treated as class variables. An unstructured variance-
covariance structure was applied to model the within-
subject errors. The primary MMRM was applied to the
CDR-SB, ADAS-Cog 13, MMSE, and FAQ endpoints, as
well as other endpoints, including CANTAB, FCSRT, and
NPI-Q. Change from baseline in PET SUVr was evaluated
using an analysis of covariance model with baseline value
and treatment as independent variables. A nonparametric
Wilcoxon test was used for percentage change from base-
line in CSF biomarkers to minimize the influence of po-
tential outliers. All reported exploratory p values refer to
comparisons between placebo and each gantenerumab
arm. Comparisons of the gantenerumab 225 mg and pla-
cebo arms did not include APOE ε4 homozygote patients.
The analysis population included all study participants
who received at least one injection of study medication.
An IDMC served as an independent group to examine
all safety and efficacy data on a roughly quarterly basis.
Rules for the preplanned futility analysis (50% patients
reaching 2-year endpoint) were such that the IDMC
would recommend study termination if the likelihood of
achieving an effect size of 0.2 at the end of the study
was < 15% based on estimates from the prespecified
MMRM analysis model for the primary endpoint.
Role of the funding source
The sponsor designed the study in consultation with the
academic authors. Data were gathered by the study in-
vestigators, analyzed by the sponsor, and interpreted in
collaboration with the academic authors. All authors
were involved in the development of the manuscript.
The academic authors had full access to the study data
and vouch for the accuracy and integrity of the data and
the fidelity of this report to the study protocols.
Results
Study population
Of 3089 screened patients, 797 (25.9%) were randomized
and received at least one injection of study medication.
At the time of the interim analysis, 316 had completed
2 years of treatment. An additional 278 were enrolled
but had not completed 2 years of treatment, and 203 pa-
tients had discontinued treatment, with the most com-
mon reasons being adverse events, self- or legal
guardian withdrawal of consent, or the initiation of
symptomatic therapies (Fig. 1).
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Baseline characteristics
There were no differences between the treatment arms
with respect to age, sex, race, education, or weight
(Table 1). By design, there were no patients homozygous
for APOE ε4 in the gantenerumab 225 mg arm. There were
no differences between treatment groups with respect to
baseline clinical scores or CSF biomarkers (Table 1).
The baseline demographics and disease characteristics
of patients in the PET substudy and those of patients
with CSF biomarker data at week 104 did not substan-
tially differ from the overall study population and were
well balanced across treatment arms (data not shown).
Interim analysis
At the preplanned interim analysis, the prespecified
stopping criterion for futility was met. With an esti-
mated value of 6%, the predictive probability of success
was below the prespecified cutoff of 15%. There was no
difference between the placebo arm and either of the
gantenerumab treatment arms in the primary endpoint
(change from baseline in CDR-SB score at 2 years). The
IDMC recommended terminating the trial for futility
based on a lack of efficacy and unrelated to safety find-
ings or concerns. This recommendation was endorsed
by the sponsor’s review board. Following this interim
Fig. 1 Enrollment, randomization, and 2-year completion in the SCarlet RoAD study. AChE Acetylcholinesterase
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analysis, dosing of study drug was halted, and the study
was unblinded. Data collected up to the time of unblind-
ing are presented here.
Therefore, all analyses presented below, including p
values, should be considered as strictly descriptive and
exploratory. In this context, no formal p value correction
for multiple testing was applied, but multiplicity was
considered in the interpretation of results.
Exploratory efficacy analysis
In addition to the primary endpoint (CDR-SB), the ana-
lysis of secondary cognitive, functional, and behavioral
endpoints also showed no treatment effect at 2 years
(Table 2, Fig. 2a and b), which is further illustrated by all
exploratory p values from the MMRM applied to CDR-
SB, ADAS-Cog 13, MMSE, and FAQ being > 0.05
(Table 2). FCSRT with Immediate Recall total recall,
CANTAB, and NPI-Q data showed no treatment effect
(data not shown).
Exploratory biomarker analysis
Exploratory biomarker analyses suggested a dose-
dependent effect of gantenerumab on brain amyloid load
as measured by PET, as well as on downstream bio-
markers of neural and synaptic degeneration (CSF tau
species and neurogranin).
Amyloid PET
There were 115 subjects with PET data at baseline, of
whom 55 had PET data at the end of 2 years of study
treatment. The mean cortical composite PET SUVr at
baseline using the prespecified mean cerebellar gray ref-
erence region was 1.68, 1.65, and 1.62 for the placebo,
105-mg, and 225-mg dose groups, respectively. The
effect of gantenerumab on PET SUVr was dose- and
time-dependent (Fig. 3). PET SUVr was reduced from
baseline by an average 4.8% (absolute mean difference
−0.09, p = 0.1 vs placebo) at week 100 in the 225-mg
dose group. There was no effect on brain amyloid load
in either the gantenerumab 105-mg dose group (0.72%
change from baseline, absolute mean difference 0.00) or
the placebo group (1.09% change from baseline, absolute
mean difference −0.02) (Fig. 3). Exploratory analyses
using alternative reference regions support that the
drug-placebo difference at the 225-mg dose level was ro-
bust (data not shown).
MRI volumetry
No difference between treatment arms at either of the
doses tested was seen for any volumetric MRI measure
investigated: whole brain, left/right hippocampal, and
ventricular volume (data not shown).
Table 1 Baseline characteristics of patients in the SCarlet RoAD study







Age, years, mean (SD) 69.5 (7.5) 70.3 (7.0) 71.3 (7.1)
Education, years, mean (SD) 89.8% 93.0% 91.9%
Weight, kg, mean (SD) 12.6 (4.3) 12.9 (4.8) 12.1 (4.5)
APOE ε4 genotype, %a 69.8 (12.9) 70.5 (13.6) 70.1 (12.5)
0ε4 29.7% 21.0% 38.5%
1ε4 50.4% 41.0% 61.5%
2ε4 19.9% 38.0% –
Clinical scores
CDR-SB, mean score (SD) 2.1 (1.0) 2.2 (1.0) 2.0 (0.9)
ADAS-Cog 13, mean score (SD) 23.5 (7.2) 23.1 (6.9) 23.0 (6.2)
FAQ, mean score (SD) 4.9 (4.3) 4.6 (3.9) 4.8 (4.3)
FCSRT-Total Recall, mean score (SD) 29.3 (10.8) 28.3 (10.8) 30.5 (10.4)
MMSE, mean score (SD) 25.7 (2.1) 25.7 (2.3) 25.7 (2.2)
CSF biomarkers
Aβ42, pg/ml, mean (SD) 487.8 (170.4) 475.3 (142.2) 511.8 (172.0)
t-tau, pg/ml, mean (SD) 556.3 (203.8) 563.2 (239.1) 544.5 (220.5)
p-tau, pg/ml, mean (SD) 84.0 (31.4) 86.3 (39.5) 82.5 (34.2)
Neurogranin, pg/ml, mean (SD) 474.8 (260.7) 500.5 (270.0) 484.9 (293.9)
Abbreviations: ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, APOE Apolipoprotein E, CDR-SB Clinical Dementia Rating Sum of Boxes, CSF
Cerebrospinal fluid, FAQ Functional Activities Questionnaire, FCSRT Free and Cued Selective Reminding Test, MMSE Mini Mental State Examination
aBy design, there were no APOE 2ε4 patients in the gantenerumab 225 mg arm
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CSF
CSF samples were not collected from all individuals
postbaseline. Statistical analysis was performed on sam-
ples from patients who had at least one postbaseline
CSF sample (n = 209). For neurogranin, the numbers
were lower because of assay performance; that is, data
from patients with neurogranin levels below the limit of
quantification were excluded. Results are summarized in
Table 3. Results suggested dose- and time-dependent re-
ductions in t-tau and p-tau (Fig. 4). At week 104, sig-
nificantly greater reductions from baseline in the
gantenerumab 105 mg and 225 mg treatment arms com-
pared with the placebo arm were observed for CSF p-tau
(p ≤ 0.001 and p ≤ 0.001, respectively) and t-tau (p = 0.05
and p = 0.02, respectively). The results also suggested a
reduction of CSF neurogranin at the higher dose
(Table 3, Fig. 4). No significant change in the levels of
CSF Aβ42 over 2 years of gantenerumab treatment com-
pared with placebo were observed, even though a nu-
merical increase was seen with gantenerumab 225 mg at
week 104 only.
Further exploratory analyses
Despite the results of the futility analysis, the presence
of a drug effect on biomarkers of target engagement and
neurodegeneration, as described above, triggered further
exploratory analyses to gain understanding of the results
of the study and to potentially guide future development
of gantenerumab. An aspect of this analysis was to
explore the impact of the observed rate of disease pro-
gression in the prodromal AD population. These ana-
lyses were limited to 2-year completers.
Before the SCarlet RoAD study was unblinded, an AD
progression model was built for CDR-SB score using the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (http://adni.loni.usc.edu/) [20]. The model dis-
tinguishes two population types: “slow” progressing and
“fast” progressing. Further statistical investigations over
a large series of potential covariates at baseline deter-
mined CDR-SB, FAQ, and hippocampal volume to be
the three main factors in predicting progression type
and a prognostic “signature” was therefore proposed as a
method to predict “fast” or “slow” progression of disease
for patients with prodromal AD.
Applying this algorithm to the SCarlet RoAD 2-year
completer population (baseline data), almost two-thirds
of the trial population were predicted to be slow pro-
gressors (n = 202), and one-third could be designated as
fast progressors (n = 108) (Table 4). By design, fast and
slow progressors have slightly different mean baseline
characteristics, with fast progressors having higher base-
line FAQ and CDR-SB and smaller hippocampal volume.
Fast progressors also included fewer APOE ε4 noncar-
riers. However, within the fast and slow subgroups, base-
line characteristics appeared well balanced between the
treatment arms (data not shown). Given the small sam-
ple size in the subgroups of this exploratory analysis, it
was deemed that median and IQR data would be ad-
equate summary statistics to report results.
Table 2 Least squares mean change in primary and secondary clinical outcomes in mixed-effects model repeated measurement
statistical analysis





p Value vs placebo LS mean
(95% CI)
p Value vs placebo
Primary endpoint
CDR-SB
Change from baseline 1.60 (1.28, 1.91) 1.69 (1.37, 2.01) – 1.73 (1.42, 2.04) –
Difference from placebo – 0.10 (−0.35, 0.54) 0.67 0.18 (−0.28, 0.63) 0.45
Secondary endpoint
ADAS-Cog 13
Change from baseline 5.77 (4.54, 6.99) 5.14 (3.91, 6.38) – 5.54 (4.21, 6.87) –
Difference from placebo – −0.62 (−2.34, 1.09) 0.48 −0.27 (−2.23, 1.70) 0.79
FAQ
Change from baseline 4.70 (3.71, 5.68) 5.93 (4.93, 6.93) – 4.57 (3.58, 5.55) –
Difference from placebo – 1.23 (−0.16, 2.62) 0.08 −0.27 (−1.72, 1.18) 0.72
MMSE
Change from baseline −2.93 (−3.50, −2.35) −3.02 (−3.60, −2.44) – −2.73 (−3.33, −2.14) –
Difference from placebo – −0.10 (−0.90, 0.71) 0.81 0.34 (−0.54, 1.22) 0.45
Abbreviations: ADAS-Cog 13 Alzheimer’s Disease Assessment Scale–Cognitive subscale, CDR-SB Clinical Dementia Rating Sum of Boxes, FAQ Functional Activities
Questionnaire, LS Least squares, MMSE Mini Mental State Examination
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In the fast progressor subgroup, results suggested a
dose-dependent slowing of decline in ADAS-Cog 13,
CANTAB, and MMSE, but not in CDR-SB score change,
from baseline at 2 years (Table 4). The slow progressor
subgroup did not show any difference in decline across
treatment groups.
Adverse events
No notable differences were seen in the rate of serious
adverse events and death across groups (Table 5). Two
adverse event terms were reported in gantenerumab-
treated patients at a rate of > 5% and twofold greater
than in the placebo arm: injection site erythema and
ARIA (Table 6).
Injection site erythema events were all mild to mod-
erate in intensity. ARIA-E events were dose- and APOE
ε4 genotype-dependent and occurred rarely in the
placebo arm. ARIA-H were also APOE ε4 genotype-
dependent and more frequent with gantenerumab treat-
ment (Table 6). ARIA-E occurred most frequently
between 3 and 6 months of treatment; the incidence
notably decreased after the first 9 months of treatment,
and ARIA-E did not commonly recur (recurrence rate
13.8%) in patients who restarted treatment at half the
original dose. The large majority of ARIA-E events (>
80%) were asymptomatic and resolved with dose
adjustment. The most commonly reported symptom
was headache.
Fig. 2 Least squares mean (±95% CI) change from baseline in CDR-SB (a) and ADAS-Cog 13 score (b). CDR-SB Clinical Dementia Rating Sum of
Boxes, ADAS-Cog 13 Alzheimer’s Disease Assessment Scale–Cognitive subscale, LS Least squares
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Discussion
In the SCarlet RoAD study, we investigated the effects of
105 mg or 225 mg of SC gantenerumab or placebo given
every 4 weeks in patients with prodromal AD. A pre-
planned futility analysis was conducted on the primary
endpoint (CDR-SB change from baseline) when ~ 50% of
the patients had completed 2 years of treatment. No dif-
ferences were observed in primary or secondary efficacy
measures across the placebo and treatment arms, and
the futility model predicted a < 6% chance of a positive
study, which prompted the sponsor to discontinue
dosing. These clinical outcomes in prodromal AD are
reminiscent of phase III trials in mild to moderate AD
with another antiaggregated Aβ antibody, bapineuzu-
mab, in which investigators explored a limited dose
range [21, 22]. Several factors were examined for their
contributions to a negative outcome in SCarlet RoAD,
including inactive compound, insufficient dosing, short
trial duration, insensitive endpoints, and the population
studied.
Despite the lack of a clinical benefit in the overall
population, gantenerumab showed evidence of biological
Fig. 3 Mean (±SE) change from baseline in PET SUVr (cerebellar gray reference). *p < 0.01 vs placebo. PET SUVr Positron emission tomography
standardized uptake value ratio
Table 3 Cerebrospinal fluid biomarker findings
Change from baseline
at week 104





p Value vs placebo Change (%),
median (Q1, Q3)
p Value vs placebo








































Abbreviations: Aβ Amyloid-beta, p-tau Phosphorylated tau, t-tau Total tau
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activity at the doses tested. Reduction of amyloid load as
measured by PET was dose-dependent, indicative of suc-
cessful target engagement in the brain and a confirm-
ation of gantenerumab’s mechanism of action in a larger
dataset and in a population at an earlier stage of the
disease than in the earlier report [8]. Furthermore, gan-
tenerumab treatment was associated with a dose-
dependent reduction in CSF biomarkers that are thought
to reflect core pathological processes of AD, including
hyperphosphorylation of tau (p-tau), and downstream
processes of neuronal and axonal degeneration (t-tau)
[23], as well as synaptic dysfunction (neurogranin) [24].
Interestingly, in a subgroup of fast progressors, numer-
ical differences in decline between treatment groups as
measured by the ADAS-Cog 13 were observed, suggesting
a dose-dependent clinical response. Similar dose-
dependent trends were observed for MMSE and CANTAB,
although not for CDR-SB. In contrast, no such effects were
seen in patients predicted to have slow progression.
In SCarlet RoAD, gantenerumab doses of 105 and
225 mg SC every 4 weeks had been chosen to minimize
the risk of ARIA in this mildly affected prodromal AD
population. Dose- and APOE ε4 genotype-dependent
ARIA were observed, as was injection site erythema.
However, most of the ARIA were asymptomatic and
rated by the investigators as mild or moderate, and most
patients could continue dosing, albeit at a lower (halved)
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Fig. 4 Percentage changes in median cerebrospinal fluid biomarker levels for Aβ1–42, p-tau, t-tau, and neurogranin. *p≤ 0.05; **p≤ 0.005; ***p≤
0.0001. Aβ Amyloid-beta, p-tau Phosphorylated tau 181
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It is hypothesized that higher doses of gantenerumab
that result in more amyloid load reduction may be more
likely to result in clinically meaningful efficacy. Recent
phase Ib study results with aducanumab, an antibody
with a preclinical profile similar to that of gantenerumab
which was tested at higher doses in a similar population
to the one enrolled in SCarlet RoAD, showed substan-
tially greater and equally dose-dependent amyloid load
reduction as measured by PET but also a higher inci-
dence of ARIA [25]. The reported phase Ib results with
aducanumab are suggestive of dose-dependent clinical
effects; however, the sample was small.
The apparent dose-dependent clinical effect in fast
progressors, combined with the biomarker outcomes in
this study with gantenerumab, as well as the positive re-
sults of the phase Ib trial for aducanumab [25], suggest
that gantenerumab may have been dosed too low to
achieve substantial clinical benefit. Achieving higher ex-
posures of gantenerumab while minimizing ARIA rates
is expected to be important for a balanced benefit-risk
profile. Because ARIA in SCarlet RoAD generally oc-
curred within the first 6 months of dosing, with po-
tentially higher frequency and/or severity at higher
doses, it is hypothesized that using titration schemes to
achieve high doses may result in substantial brain amyl-
oid reduction that may be clinically beneficial yet
minimize both the rate and severity of ARIA events [26].
To test this hypothesis, multiple dose titration regimens
are being examined for their ability to minimize ARIA
events at higher doses in open-label extensions of the
ongoing gantenerumab trials. Whether treatment with
an antibody such as gantenerumab at a higher dose pro-
vides not only a higher degree of brain amyloid reduc-
tion but also a clinical benefit must be demonstrated in
randomized, placebo-controlled phase III clinical trials.
It has been questioned whether it is possible to ob-
serve clinically meaningful effects in prodromal AD pop-
ulations within a 2-year study duration. Although
negative phase III trials of anti-Aβ antibodies in mild
and moderate AD have been 18 months long [21, 27],
the phase Ib study results with aducanumab mentioned
above suggest that clinical effects in an AD population
at an earlier stage of the disease can already be identified
after 12 months [25]. Therefore, the 2-year study dur-
ation in SCarlet RoAD was likely sufficient to show clin-
ically meaningful effects.
The sensitivity of endpoints to effectively capture
change in prodromal AD may potentially contribute to
negative trial outcomes in this population. The primary
endpoint in SCarlet RoAD was change in CDR-SB score
over 2 years, in alignment with guidance from health
authorities [28, 29] and other groups [30]. Recent ana-
lysis of the CDR-SB demonstrated test-retest reliability,
construct validity to functional change, and sensitivity to
decline in AD [31, 32]. SCarlet RoAD was the first global
phase III study in prodromal AD using amyloid screen-
ing. The decline observed in the placebo group was
slightly less (1.60 CDR-SB points over 2 years) than ex-
pected on the basis of ADNI data (1.92 CDR-SB points
over 2 years) available at the time at which the study
was designed. However, in another randomized clinical
trial in CSF biomarker-supported prodromal AD, the de-
cline in mean CDR-SB points over 2 years (placebo
group) was reported to be 1.65 [33]. Hence, the observed
decline in CDR-SB is consistent with another recent
clinical trial. Other, older reports [34] had suggested a
higher placebo decline, but these were observational
studies and had other important differences in terms of
study design and patient characteristics. The change
from baseline in CDR-SB was consistent with changes




Change from baseline at week 104 (n = 310a)
Slow progressors (n = 202) Fast progressors (n = 108)













CDR-SB 0.5 (0, 1.5) 0.5 (0, 2) 1.0 (0, 1.5) 1.5 (0.5, 3) 1.0 (0, 2.75) 2.0 (1, 2.88)
Secondary endpoints
ADAS-Cog 13 3.34 (−1.41, 8.41) 3.5 (−2.5, 6.25) 3.33 (−0.34, 8.67) 6.0 (2.34, 12.17) 4.84 (1.5, 7.92) 2.66 (0.67, 7.5)
CANTAB −1.43 (−2.52, −0.31) −1.14 (−3, 0.97) −0.99 (−3.22, 0.56) −2.42 (−4.09, 0.07) −1.31 (−3.27, 0.25) −0.81 (−1.98, 0.69)
FAQ 1 (0, 5) 1 (0, 7) 2 (0, 6) 5 (2.5, 8) 6 (2, 8.5) 4 (1, 9)
MMSE −1 (−4, 0) −1 (−4, 0.25) −2 (−3, 0) −3.5 (−4.75, −2) −3 (−4.5, 0) −2 (−4, 0)
Abbreviations: ADAS-Cog 13 Alzheimer’s Disease Assessment Scale–Cognitive subscale, CANTAB Cambridge Neuropsychological Test Automated Battery, CDR-SB
Clinical Dementia Rating Sum of Boxes, FAQ Functional Activities Questionnaire, MMSE Mini Mental State Examination
aSix patients completing study drug treatment had missing efficacy assessment at the week 104 visit time window
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Table 5 Summary of adverse events







Any adverse event 250 (94.0%) 241 (88.9%) 240 (92.3%)
Any serious adverse event 55 (20.7%) 48 (17.7%) 46 (17.7%)
Any death 6 (2.3%) 0 2 (0.8%)
Cardiac disorders 24 (9.0%) 26 (9.6%) 22 (8.5%)
Ear and labyrinth disorders 11 (4.1%) 15 (5.5%) 13 (5.0%)
Eye disorders 20 (7.5%) 16 (5.9%) 23 (8.8%)
Gastrointestinal disorders 65 (24.4%) 64 (23.6%) 63 (24.2%)
Diarrhea 14 (5.3%) 15 (5.5%) 15 (5.8%)
General disorders and administration site conditions 44 (16.5%) 78 (28.8%) 90 (34.6%)
Injection site erythema 3 (1.1%) 29 (10.7%) 35 (13.5%)
Fatigue 8 (3.0%) 7 (2.6%) 15 (5.8%)
Infections and infestations 110 (41.4%) 110 (40.6%) 119 (45.8%)
Nasopharyngitis 17 (6.4%) 30 (11.1%) 20 (7.7%)
Urinary tract infection 26 (9.8%) 16 (5.9%) 22 (8.5%)
Upper respiratory tract infection 11 (4.1%) 13 (4.8%) 18 (6.9%)
Influenza 13 (4.9%) 13 (4.8%) 15 (5.8%)
Bronchitis 10 (3.8%) 10 (3.7%) 14 (5.4%)
Injury, poisoning, and procedural complications 73 (27.4%) 65 (24.0%) 59 (22.7%)
Fall 28 (10.5%) 23 (8.5%) 28 (10.8%)
Investigations 40 (15.0%) 35 (12.9%) 48 (18.5%)
Metabolism and nutrition disorders 23 (8.6%) 21 (7.7%) 24 (9.2%)
Musculoskeletal and connective tissue disorders 82 (30.8%) 72 (26.6%) 72 (27.7%)
Back pain 26 (9.8%) 16 (5.9%) 25 (9.6%)
Arthralgia 20 (7.5%) 12 (4.4%) 16 (6.2%)
Musculoskeletal pain 15 (5.6%) 6 (2.2%) 5 (1.9%)
Neoplasms benign, malignant, and unspecified
(including cysts and polyps)
20 (7.5%) 16 (5.9%) 21 (8.1%)
Nervous system disorders 123 (46.2%) 126 (46.5%) 127 (48.8%)
Headache 36 (13.5%) 34 (12.5%) 25 (9.6%)
Dizziness 21 (7.9%) 21 (7.7%) 27 (10.4%)
Psychiatric disorders 76 (28.6%) 65 (24.0) 73 (28.1%)
Depression 14 (5.3%) 23 (8.5%) 25 (9.6%)
Anxiety 19 (7.1%) 20 (7.4%) 16 (6.2%)
Renal and urinary disorders 19 (7.1%) 21 (7.7%) 22 (8.5%)
Reproductive system and breast disorders 12 (4.5%) 14 (5.2%) 15 (5.8%)
Respiratory, thoracic, and mediastinal disorders 32 (12.0%) 29 (10.7%) 33 (12.7%)
Skin and subcutaneous tissue disorders 31 (11.7%) 39 (14.4%) 39 (15.0%)
Surgical and medical procedures 21 (7.9%) 18 (6.6%) 18 (6.9%)
Vascular disorders 33 (12.4%) 19 (7.0%) 30 (11.5%)
Hypertension 18 (6.8%) 11 (4.1%) 19 (7.3%)
Events with an incidence of at least 5% in any treatment group are shown
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observed in other measures of cognition (ADAS-Cog 13,
MMSE) and function (FAQ). The sensitivity of CDR-SB
to drug effects has also been suggested by the aducanu-
mab phase Ib study, as mentioned above. Overall, the
choice of CDR-SB as the primary endpoint seemed ap-
propriate for the population examined. The observed
rate of decline must be carefully considered in any sam-
ple size estimation for future studies if the same popula-
tion is to be enrolled.
This report has important limitations. The study was
stopped early for futility. All biomarker and clinical sig-
nals described resulted from exploratory analyses, some
of which were conducted post hoc. Therefore, all ana-
lyses presented here, including p values, should be con-
sidered as strictly descriptive and hypothesis-generating,
but not confirmatory.
Conclusions
In summary, although the SCarlet RoAD study was
stopped early for futility, dose-dependent effects ob-
served in exploratory analyses on select clinical and bio-
marker endpoints suggest that higher dosing with
gantenerumab may be necessary to achieve clinical effi-
cacy. Exploratory analyses in a fast progressor subgroup
were also suggestive of a dose-dependent effect of gante-
nerumab on some clinical endpoints. Growing evidence
of the manageability of ARIA supports the investigation
of higher doses of gantenerumab in subsequent clinical
trials. Further phase III clinical trials employing dose ti-
tration schemes designed to mitigate the increased rate
of ARIA-E expected at higher doses are planned to as-
sess the degree of amyloid reduction by gantenerumab
at these doses and to confirm whether such effects are
associated with clinical benefits.
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